Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- US stocks on course for lower open as AI jitters hit Nvidia, chipmakers
- Global AI stocks fall as industry chiefs call for slowing development
- Oil prices continue surge, rising 3% as attacks halt Saudi pipeline
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street's new pair trade: Long software, short chips
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Arrowhead Pharma (ARWR) ENaC News 'Not Thesis Changing', RBC Says; PT Lowered to $83
July 2, 2021 12:16 PM EDTRBC Capital analyst Luca Issi lowered the price target on Arrowhead Pharma (NASDAQ: ARWR) to $83.00 (from $90.00) while maintaining a Outperform rating following news the company is voluntarily pausing the Phase I/II trial for ENaC due to local lung inflammation seen in rats.... More
Arrowhead Pharma (ARWR) Defended at Citi Following ENAC Setback
July 2, 2021 10:02 AM EDTCiti analyst Mohit Bansal came out to defend Arrowhead Pharma (NASDAQ: ARWR) amid the sharp drop in the stock after pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with... More
Arrowhead (ARWR) Falls 22% After Pausing ARO-ENaC Phase 1/2 Clinical Study
July 2, 2021 7:45 AM EDTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Falls 22% After Pausing ARO-ENaC Phase 1/2 Clinical Study
... More